NYU Langone Health
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NYU Langone Health
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
- Academic and Research Institutions
- Other Names / Subsidiaries
- New York University Langone Medical Center